Prevalence and clinicopathological differences between type I and type II of endometrial cancer

被引:0
作者
Akhavan, Setare [1 ]
Mohseni, Mona [1 ]
Gilani, Mitra Modares [1 ]
Mousavi, Azam Sadat [1 ]
Sheikhhasani, Shahrzad [1 ]
Feizabad, Elham [1 ,2 ]
机构
[1] Univ Tehran Med Sci, Vali Asr Hosp, Dept Gynecol Oncol, Tehran, Iran
[2] Univ Tehran Med Sci, Yas Hosp, Dept Obstet & Gynecol, Tehran, Iran
来源
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES | 2021年 / 15卷 / 03期
关键词
Endometrial cancer; Cancer stage; Prognosis; Survival; CARCINOMA; PATHOLOGY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of this study was to evaluate the prevalence and clinicopathological differences between type I and type II endometrial cancer. Methods: This retrospective study was carried out on 480 histological confirmed endometrial cancer women (362 Type I and 118 Type II patients), diagnosed and treated in Imam Khomeini hospital from March 2010 to February 2021. Results: The average age of these 480 patients was 55.94 +/- 10.19 with the age range of 27 to 84. Of them, 72.1% were post-menopausal and 13.5% were nulliparous. The two most common presentations of EC were postmenopausal vaginal bleeding and menometrorrhagia. The three survival rate, and five survival rate was 382 (95.3%), and 271 (83.4%), respectively with significantly (pvalue<0.001) higher proportion in three and five survival rate in Type II. The survival rate based on tumor stages demonstrated a better rate in low stages compared to high stages. In addition, disease recurrence occurred in 17.1% (82) of patients with significant (p-value<0.001) more prevalent in Type II of tumor. Conclusions: The findings of this study recommend that the higher mortality rate of type II endometrial cancer might be due to its high stage at the time of diagnosis. Accordingly, comprehensive screening is likely to increase the survival rate in this curable cancer.
引用
收藏
页码:992 / 995
页数:4
相关论文
共 22 条
[1]   Comparison of Crude and Age-Specific Incidence Rates of Breast, Ovary, Endometrium and Cervix Cancers in Iran, 2005 [J].
Arab, Maliheh ;
Noghabaei, Giti ;
Kazemi, Seyyedeh Neda .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) :2461-2464
[2]   Endometrial Adenocarcinoma: Clinicopathologic and Survival Characteristics in Yazd, Iran [J].
Binesh, Fariba ;
Akhavan, Ali ;
Behniafard, Nasim ;
Jalilian, Samaneh .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) :2797-2801
[3]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[4]   Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Colombo, N. ;
Preti, E. ;
Landoni, F. ;
Carinelli, S. ;
Colombo, A. ;
Marini, C. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2011, 22 :vi35-vi39
[5]   Carcinoma of the corpus uteri [J].
Creasman, WT ;
Odicino, F ;
Maisonneuve, P ;
Beller, U ;
Benedet, JL ;
Heintz, APM ;
Ngan, HYS ;
Pecorelli, S .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 83 :79-118
[6]  
ELBOLKAINY MN, 1981, CANCER-AM CANCER SOC, V48, P2643, DOI 10.1002/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO
[7]  
2-C
[8]   Hormonal interactions in endometrial cancer [J].
Emons, G ;
Fleckenstein, G ;
Hinney, B ;
Huschmand, A ;
Heyl, W .
ENDOCRINE-RELATED CANCER, 2000, 7 (04) :227-242
[9]  
Esteller M, 1999, ONCOL REP, V6, P1377
[10]   Factors associated with Type I and Type II endometrial cancer [J].
Felix, Ashley S. ;
Weissfeld, Joel L. ;
Stone, Roslyn A. ;
Bowser, Robert ;
Chivukula, Mamatha ;
Edwards, Robert P. ;
Linkov, Faina .
CANCER CAUSES & CONTROL, 2010, 21 (11) :1851-1856